ProKidney narrowed its net loss in Q2 2025 and strengthened its regulatory position with the FDA for rilparencel, supported by strong topline data and a robust cash balance.

ProKidney Corp. reported a net loss of $16.734 million for the three months ended March 31, 2025, with operating expenses totaling $41.618 million, primarily driven by research and development activities. The company generated $0.230 million in revenue from leasing activities and maintained a strong cash position with $97.805 million in cash and cash equivalents.

ProKidney reported its Q3 2024 financial results, highlighting a successful FDA Type B meeting where the FDA confirmed the PROACT 1 Phase 3 study could support a full U.S. regulatory approval of rilparencel and that the accelerated approval pathway is available. The company ended the quarter with $406.8 million in cash and cash equivalents, supporting operations into 2027.

ProKidney reported positive interim REGEN-007 data, restarted manufacturing, resumed PROACT 1 and PROACT 2 Phase 3 trials, and closed a $140 million equity offering. The company ended the quarter with $431.5 million in cash and cash equivalents and marketable securities.

ProKidney ended the first quarter of 2024 with $329 million in cash and cash equivalents. The company is on schedule to resume manufacturing and PROACT 1 Phase 3 trial, commence PROACT 2 Phase 3 trial, and readout interim results from the ongoing REGEN-007 Phase 2 trial in mid-2024.

ProKidney Corp. reported its full-year 2023 financial results, highlighting positive interim Phase 2 data for rilparencel and key corporate updates, including the appointment of Dr. Bruce Culleton as CEO and Nikhil Pereira-Kamath as Chief Business Officer. The company's cash, cash equivalents, and marketable securities totaled $363.0 million as of December 31, 2023, expected to fund operations into the fourth quarter of 2025.

ProKidney reported having nearly $400 million in cash, cash equivalents and marketable securities as of September 30, 2023, and expects cash to fund operations into the fourth quarter of 2025. Research and development expenses were $32.2 million and general and administrative expenses were $14.4 million for the three months ended September 30, 2023. Net loss before noncontrolling interest was $42.0 million for the three months ended September 30, 2023.

ProKidney reported financial results for the second quarter ended June 30, 2023. The company had cash, cash equivalents and marketable securities totaling $446.1 million as of June 30, 2023. Research and development expenses were $26.4 million for the three months ended June 30, 2023, and general and administrative expenses were $13.5 million for the same period. Net loss before noncontrolling interest was $34.8 million for the three months ended June 30, 2023.

ProKidney reported its Q1 2023 financial results, highlighting the advancement of the Phase 3 clinical development of REACT and plans for manufacturing and organizational development. The company's cash, cash equivalents, and marketable securities totaled $463.7 million as of March 31, 2023.

ProKidney reported its Q4 2022 financial results, highlighting a cash position of $490.3 million, R&D expenses of $20.9 million, and G&A expenses of $9.3 million. The company's net loss before noncontrolling interest was $24.6 million.

ProKidney reported financial results for the third quarter ended September 30, 2022. The company made significant advancements in its mission to improve the lives and outcomes for people with CKD, including listing on the Nasdaq and raising capital.

ProKidney reported its financial results for the second quarter ended June 30, 2022. The company completed its business combination with Social Capital Suvretta Holdings, III, receiving gross proceeds of $596.5 million. Research and development expenses were $11.6 million, while general and administrative expenses were $9.2 million. The company's cash and cash equivalents totaled $21.9 million as of June 30, 2022.